Akers Biosciences Inc (Nasdaq:AKER) and its proposed merger partner MyMD Pharmaceuticals Inc reported on Thursday the publication of a new study showing the effects of temperature changes on the transmission of SARS-CoV-2, the virus that causes COVID-19.
The study, authored by Adam Kaplin, MD, PhD, chief scientific officer of MyMD Pharmaceuticals, suggests that between the range of 30 to 100 degrees Fahrenheit a one-degree temperature increase is associated with a 1% decrease in the rate of COVID-19 transmission and a one-degree temperature decrease is associated with a 3.7% increase in the rate of transmission. The research was based on 50 Northern Hemisphere countries.
Knowledge of COVID-19 seasonality could feed into local planning for phased reductions, social interventions and preparing for the timing of possible pandemic resurgence during cooler months.
The study has been published in PLOS ONE.
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
LynxKite Technologies expands Biophytis collaboration
BioDlink named 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Emerald Clinical Trials honoured with 2026 Asia Pacific Biopharma Excellence Award